Myoclonus as a Single Side Effect of Combination of Selective Serotonin Reuptake Inhibitors (SSRIs) and Clomipramine: Three Case Reports
Authors
Abstract:
Selective Serotonin Reuptake Inhibitors (SSRIs) are the most popular psychiatric medications that are approved for several neuropsychiatric conditions such as depression and obsessive-compulsive disorder (OCD). On the other hand, clomipramine is a tricyclic anti-depressant which is the only approved medication, among this class, to treat OCD due to its substantial effects on serotonergic system. Combination of SSRIs and clomipramine is uncommon in routine psychiatric practice because it can increase the risk of serotonin syndrome which is characterized by myoclonus, headache, nausea, confusion, diarrhea, tremor, twitching muscles, and agitation. However, it could be useful in patients suffering from treatment-resistant OCD. Here, we describe three cases of OCD patients, treated by combination of SSRIs and clomipramine who showed only myoclonic movements in initial week without any other manifestations of the serotonin syndrome. In less than one week after initiation of medication, abnormal movements disappeared, and in six month follow-up evaluation, the patients were observed with considerable improvements. Indeed, myoclonic movements is not a predictor of full-blown serotonin syndrome when combination of SSRIs and clomipramine is used. Therefore, the combination could be a considerable approach in treatment of refractory OCD.
similar resources
Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery.
BACKGROUND Stroke is the major cause of adult disability. Selective serotonin reuptake inhibitors (SSRIs) have been used for many years to manage depression. Recently, small trials have demonstrated that SSRIs might improve recovery after stroke, even in people who are not depressed. Systematic reviews and meta-analyses are the least biased way to bring together data from several trials. Given ...
full textSelective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) for the prevention of migraine in adults.
BACKGROUND This is an updated version of the original Cochrane review published in 2005 on selective serotonin reuptake inhibitors (SSRIs) for preventing migraine and tension-type headache. The original review has been split in two parts and this review now only regards migraine prevention. Another updated review is under development to cover tension-type headache.Migraine is a common disorder....
full textSelective Serotonin Reuptake Inhibitors
It has long been postulated that a deficiency in CNS serotonergic activity is the cause of, or a predisposing factor for, depression. [1] However, the evidence for this association is largely circumstantial and it certainly does not represent an adequate and full model for depression, probably due to there being multiple aetiological factors. [2] Some pharmacological trial data also cast doubt ...
full textEmotional side-effects of selective serotonin reuptake inhibitors: qualitative study.
BACKGROUND Some people who take selective serotonin reuptake inhibitor (SSRI) antidepressants report that their experience of emotions is 'blunted'. This phenomenon is poorly understood. AIMS To understand patients' experiences of this phenomenon. METHOD Qualitative study, gathering data through individual interviews, a group interview and validation interviews; and searching patient websit...
full textselective serotonin reuptake inhibitors and cardiovascular events: a systematic review
background: given the importance of the role of depression in predicting the outcome of cardiovascular disorders, current medications for treating depression, particularly selective serotonin reuptake inhibitors (ssris), are taken into consideration. this study aimed to systematically review the published findings in the use of ssris and the risk for cardiac events. materials and methods: an i...
full textMy Resources
Journal title
volume 30 issue 186
pages 163- 169
publication date 2020-07
By following a journal you will be notified via email when a new issue of this journal is published.
No Keywords
Hosted on Doprax cloud platform doprax.com
copyright © 2015-2023